ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.Frontiers in psychiatry · 2022Pooled it
- Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis.The International journal on drug policy · 2021Pooled it
- Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.Drug and alcohol dependence · 2019Pooled it
- The effect of daily aerobic cycling exercise on cannabis withdrawal: An inpatient randomised controlled trial.Scientific reports · 2026Trial
- Signaling-specific inhibition of the CBNature medicine · 2023Trial
- Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.Substance abuse treatment, prevention, and policy · 2022Trial
- Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial.Drug and alcohol dependence · 2021Trial
- Beyond abstinence: Redefining success in cannabis use disorder treatment.Addiction (Abingdon, England) · 2026Article
- Identifying and addressing cannabis withdrawal syndrome.Journal of military, veteran and family health · 2026Article
- Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.Current topics in behavioral neurosciences · 2026Review
- Article
- Article
- Cannabis Use in Adolescents.Delaware journal of public health · 2025Article
- The Bidirectional Interplay Between Substances of Abuse and Gut Microbiome Homeostasis.Life (Basel, Switzerland) · 2025Review
- The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists.The American journal of psychiatry · 2024Review
- Review
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.Molecular psychiatry · 2024Article
- A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.BMC psychiatry · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.